Patients meeting the following criteria are considered eligible for treatment with clozapine oro-dispersible:

1. As an alternative for patients already established on clozapine suspension.
2. To support establishment of clozapine treatment for patients reluctant to swallow tablets.
3. To aid compliance monitoring in patients with a known history of oral non-compliance.
4. Patients with a diagnosed swallowing difficulty who cannot swallow tablets.
5. A non-formulary request has been submitted to and approved by the Prescribing Management Group (PMG(MH).

Note: the standard tablets are the preparation of choice. Patients, where possible, should be switched to standard tablets at the earliest opportunity.

If use of clozapine oro-dispersible tablets is approved the following process must be completed before clozapine oro-dispersible can be prescribed:

1. The consultant psychiatrist, treatment location and patient must be registered with ZTAS
2. Confirmation of this registration must be received by pharmacy and the consultant psychiatrist before clozapine oro-dispersible is prescribed.
3. Inpatient- new clozapine initiation: Prescribe the appropriate titration regime on HEPMA and inform Leverndale pharmacy via telephone or email. If a paper titration form is being used then this should be emailed to Leverndale Pharmacy and prescribed on HEPMA as ‘clozapine loading regime- as charted’.
4. Inpatient- formulation change: Prescribe appropriately on HEPMA and inform Leverndale Pharmacy of the change via telephone or email.
5. For outpatients: Prescribe appropriately on a clozapine outpatient prescription form and email the prescription to Leverndale Pharmacy. This should be a new entry on the prescription form and NOT oro-dispersible added to existing clozapine.
6. Amend the clozapine warning on EMIS to highlight the use of oro-dispersible tablets.